Trevi Therapeutics, Inc.TRVINASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank44
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-28.62M
↓ 16% vs avg
Percentile
P44
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-24.58M
Historical baseline
PeriodValueYoY Change
TTM$-28.62M+25.2%
2024$-38.29M-20.2%
2023$-31.85M-12.4%
2022$-28.33M+2.1%
2021$-28.95M+0.3%
2020$-29.03M-25.7%
2019$-23.10M-25.2%
2018$-18.45M-131.0%
2017$-7.99M+28.6%
2016$-11.19M-